{{Rsnum
|rsid=7992226
|Gene=NALCN
|Chromosome=13
|position=101145489
|Orientation=plus
|GMAF=0.1938
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=NALCN
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 46.9 | 43.4 | 9.7
| HCB | 83.7 | 15.6 | 0.7
| JPT | 74.8 | 22.5 | 2.7
| YRI | 74.3 | 24.3 | 1.4
| ASW | 61.8 | 36.4 | 1.8
| CHB | 83.7 | 15.6 | 0.7
| CHD | 0.0 | 0.0 | 0.0
| GIH | 44.0 | 38.0 | 18.0
| LWK | 72.5 | 27.5 | 0.0
| MEX | 75.0 | 23.2 | 1.8
| MKK | 60.1 | 35.9 | 3.9
| TSI | 61.4 | 37.6 | 1.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs7992226
|Name_s=
|Gene_s=NALCN
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: A, MAF= 0.25, combined P value= 1.28E-04. It is also associated with greater methotrexate clearance.
|Drugs=methotrexate
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470193
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs7992226
|overall_frequency_n=23
|overall_frequency_d=128
|overall_frequency=0.179688
|n_genomes=18
|n_genomes_annotated=0
|n_haplomes=19
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}